Cordis Selution SLR PTA Drug-Eluting Balloon Launched in Japan 

May 6, 2026—Cordis announced the launch in Japan of the Selution SLR percutaneous transluminal angioplasty (PTA) drug-eluting balloon (DEB) for the treatment of peripheral artery disease. The Selution SLR PTA DEB is designed to deliver sirolimus in a controlled, sustained manner to reduce restenosis and restore vessel function, noted the company.

According to Cordis, the SELUTION SFA Japan clinical trial demonstrated durable clinical outcomes in a complex patient population with 81.5% primary patency and 93.8% of patients remaining free from reintervention through 3 years.

The 3-year results from the SELUTION SFA Japan trial were presented in April 2025 at JET2025, the Japan Endovascular Treatment conference held in Osaka, Japan. The results were published in November 2025 in JACC: Cardiovascular Interventions by Yoshimitsu Soga, MD, and Osamu Iida, MD, et al.

Dr. Soga and Dr. Iida are the Coprincipal Investigators of the SELUTION SFA Japan trial.

“I am pleased to see Selution SLR DEB now available for use in clinical practice in Japan,” commented Dr. Soga in the Cordis press release. “The 3-year results from the SELUTION SFA Japan clinical trial demonstrate sustained efficacy and safety, supporting its role as an important treatment option for patients.”

Dr. Iida added, “Selution SLR DEB is a valuable addition to the treatment options for peripheral vascular disease. In my early clinical experience, I’ve observed strong postprocedural blood flow without evidence of downstream effects below the knee. I look forward to seeing its broader adoption in real-world clinical practice.”